ABSTRACT
A 56-year-old man was revealed to be HCC with portal vein tumor thrombus. Curative operation was impossible because we recognized many daughter lesions in the liver. Tumor marker was very high. DSM-TACE was conducted as the first line therapy. There was no remarkable side effect. After two-course, the size of HCC was decreased in CT and tumor marker was normalized. Generally speaking, a prognosis of HCC with portal vein tumor thrombus is poor. Hence, DSM-TACE is one of the effective therapies for HCC with portal vein tumor thrombus.
Subject(s)
Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic/methods , Liver Neoplasms/therapy , Venous Thrombosis/etiology , Humans , Male , Microspheres , Middle Aged , Neoplastic Cells, Circulating , StarchABSTRACT
A 68-year-old man was found to have a gallbladder cancer. Curative operation was impossible because the gallbladder cancer invaded around the gallbladder in CT on 15th of April, 2008. S-1 monotherapy (120 mg/day) was started. S-1 was given orally twice daily for 4 weeks followed by 2 weeks without a treatment. There was no remarkable side effect. The gallbladder cancer was smaller in CT on 25th of September, 2008, and we confirmed a partial response (PR) in CT on 13th of February, 2009. In a pilot phase II study of S-1 for biliary tract cancer, the overall objective response rate was 35.0%. There was no severe side effect. S-1 is one of the effective drugs for biliary tract cancer.